Kyle Dempsey
Director/Board Member at OPTINOSE, INC.
Net worth: 6 089 $ as of 2024-04-29
Kyle Dempsey active positions
Companies | Position | Start | End |
---|---|---|---|
OPTINOSE, INC. | Director/Board Member | 2021-12-09 | - |
Independent Dir/Board Member | 2021-12-09 | - | |
HLS THERAPEUTICS INC. | Director/Board Member | 2022-11-28 | - |
Independent Dir/Board Member | 2022-11-28 | - | |
MVM Partners LLC | Private Equity Investor | 2017-08-31 | - |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Director/Board Member | - | - |
Career history of Kyle Dempsey
Training of Kyle Dempsey
Harvard Medical School | Doctorate Degree |
Bowdoin College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Statistics
International
United States | 7 |
Canada | 2 |
Operational
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Private Equity Investor | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 4 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
OPTINOSE, INC. | Health Technology |
HLS THERAPEUTICS INC. | Health Technology |
Private companies | 2 |
---|---|
MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Stock Market
- Insiders
- Kyle Dempsey
- Experience